T2 Biosystems Announces Commercial Expansion Through Middle East Distributor
06 Mayo 2024 - 3:34PM
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection
of sepsis-causing pathogens and antibiotic resistant genes, today
announced the execution of a territory exclusive distribution
agreement in Qatar. Under the terms of the agreement, T2 Biosystems
will sell T2Dx® Instruments, the T2Bacteria® Panel, the T2Candida®
Panel, and the T2Resistance® Panel through the newly appointed
distributor.
The execution of this exclusive distribution
agreement further expands T2 Biosystems’ commercialization in the
Middle East. Qatar’s National Sepsis Program is a collaboration
between the Ministry of Public Health and leading medical centers
that guides the national sepsis prevention efforts in the country.
Qatar’s strong focus on sepsis care is demonstrated by sepsis
mortality rates among the best in the world and a regular National
Sepsis Symposium. The introduction of the T2Dx Instrument and
sepsis panels into Qatar will allow rapid detection of
sepsis-causing pathogens and antibiotic resistance genes, in hours
instead of days, enabling clinicians to achieve targeted therapy,
faster.
"We are committed to expanding our
commercialization globally and our partnerships in the Middle East
are a very important component of our international strategy,”
stated John Sperzel, Chairman and CEO of T2 Biosystems. “We believe
this region represents strong growth potential for our
culture-independent rapid diagnostics and look forward to building
a lasting relationship with our newly appointed distributor as we
work to improve the quality of care for patients at risk of
sepsis.”
About T2 BiosystemsT2
Biosystems, a leader in the rapid detection of sepsis-causing
pathogens and antibiotic resistance genes, is dedicated to
improving patient care and reducing the cost of care by helping
clinicians effectively treat patients faster than ever before. T2
Biosystems’ products include the T2Dx® Instrument, the T2Bacteria®
Panel, the T2Candida® Panel, the T2Resistance® Panel, and the
T2Biothreat™ Panel, and are powered by the proprietary T2 Magnetic
Resonance (T2MR®) technology. T2 Biosystems has an active pipeline
of future products, including the U.S. T2Resistance Panel, the
Candida auris test, and the T2Lyme™ Panel. For more information,
please visit www.t2biosystems.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. All statements contained in this press release
that do not relate to matters of historical fact should be
considered forward-looking statements, including, without
limitation, statements about global commercial expansion and
international strategy, and the potential for growth in the region,
as well as statements that include the words “expect,” “may,”
“should,” “anticipate,” and similar statements of a future or
forward-looking nature. These forward-looking statements are based
on management’s current expectations. These statements are neither
promises nor guarantees, but involve known and unknown risks,
uncertainties and other important factors that may cause actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements, including, but not
limited to, (i) any inability to (a) realize anticipated benefits
from commitments, contracts or products; (b) successfully execute
strategic priorities; (c) bring products to market; (d) expand
product usage or adoption; (e) obtain customer testimonials; (f)
accurately predict growth assumptions; (g) realize anticipated
revenues; (h) incur expected levels of operating expenses; or (i)
continue as a going concern; or (i) increase the number of
high-risk patients at customer facilities; (ii) failure of early
data to predict eventual outcomes; (iii) failure to make or obtain
anticipated FDA filings or clearances within expected time frames
or at all; or (iv) the factors discussed under Item 1A. “Risk
Factors” in the Company’s Annual Report on Form 10-K for the year
ended December 31, 2022, filed with the U.S. Securities and
Exchange Commission, or SEC, on March 31, 2023, and other filings
the Company makes with the SEC from time to time, including our
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
These and other important factors could cause actual results to
differ materially from those indicated by the forward-looking
statements made in this press release. Any such forward-looking
statements represent management’s estimates as of the date of this
press release. While the Company may elect to update such
forward-looking statements at some point in the future, unless
required by law, it disclaims any obligation to do so, even if
subsequent events cause its views to change. Thus, no one should
assume that the Company’s silence over time means that actual
events are bearing out as expressed or implied in such
forward-looking statements. These forward-looking statements should
not be relied upon as representing the Company’s views as of any
date subsequent to the date of this press release.
Investor Contact:Philip Trip Taylor, Gilmartin
Groupir@T2Biosystems.com 415-937-5406
T2 Biosystems, Inc. has filed a
registration statement for a Form S-1 (including a preliminary
prospectus) with the Securities and Exchange Commission, or the
SEC, for the public offering. Before you invest, you should read
the Preliminary Prospectus and the other documents T2 Biosystems,
Inc. has filed with the SEC for more complete information about T2
Biosystems, Inc. and the public offering. You may get these
documents for free by visiting EDGAR on the SEC web site at
www.sec.gov. Alternatively, T2 BioSystems, Inc., A.G.P. or any
dealer participating in the public offering will arrange to send
you the Preliminary Prospectus if you request it by contacting
A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor,
New York, NY 10022, or by telephone at (212) 624-2060.
T2 Biosystems (NASDAQ:TTOO)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
T2 Biosystems (NASDAQ:TTOO)
Gráfica de Acción Histórica
De May 2023 a May 2024